Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-Intron plus REBETOL in Hepatitis C Non-Responders
NCT00039871Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2002
- Primary completion
- Sep 2007
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
01
Overview
A Phase 3 trial of peginterferon alfa-2b in hepatitis C (HCV), sponsored by Merck & Co.. Started May 2002; status: completed.
02
Drugs
peginterferon alfa-2b
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00039871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00039871.